Reprogramming muscle proteostasis in cancer cachexia: Transcriptional mechanisms and therapeutic opportunities
Cancer Letters · 2027-01 · 664 · 218944
DOI: 10.1016/j.canlet.2026.218944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2027-01. Verfasst von Bowen Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Muscle Biology and Cachexia, University of Houston College of Pharmacy, Houston, TX, 77204, USA; Department of Biomedical Engineering, U…. Die Arbeit nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, NCI NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Cancer cachexia is a multifactorial syndrome characterized by progressive skeletal muscle wasting that impairs quality of life, limits responses to anticancer therapies, and increases mortality. Although excessive protein degradation has traditionally been viewed as a primary driver of muscle loss, cachectic muscle undergoes broader disruptions in proteostasis involving protein turnover, organelle quality control, stress adaptation, metabolism, and regenerative capacity. Accumulating evidence suggests that diverse tumor- and host-derived signals converge on interconnected transcriptional networks that coordinate these processes. Rather than functioning independently, transcription factors integrate inflammatory, metabolic, hormonal, and cellular-stress signals to orchestrate catabolic, stress-responsive, anabolic, and regenerative programs, with effects that vary with disease stage and cellular context. Importantly, these transcriptional responses are not uniformly pathological but can represent causal, adaptive, or compensatory programs. Epigenetic, post-transcriptional, and post-translational mechanisms add further regulatory layers that shape the activation and magnitude of these transcriptional programs. Emerging single-cell and multi-omic approaches have further revealed myofiber- and cell-specific regulatory networks that contribute to the heterogeneous response of skeletal muscle to tumor growth. In this review, we propose that transcriptional reprogramming represents a central integrative mechanism through which diverse catabolic signals remodel skeletal muscle proteostasis, and we examine how network-level regulation contributes to muscle adaptation and wasting in cancer cachexia. Defining which regulatory programs are causal, maladaptive, adaptive, or compensatory may reveal more precise biomarkers and therapeutic targets for preserving skeletal muscle mass and function in patients with cancer cachexia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Muscle Biology and Cachexia, University of Houston College of Pharmacy, Houston, TX, 77204, USA; Department of Biomedical Engineering, University of Houston Cullen College of Engineering, Houston, TX, 77204…
- Institute of Muscle Biology and Cachexia, University of Houston College of Pharmacy, Houston, TX, 77204, USA; Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston…
Förderung
- NIAMS NIH HHS
- NCI NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health National Cancer Institute
Zitieren
APA
Xu, B., Jaiswal, A., Liu, S., Kumar, A., & Tomaz da Silva, M. (2027). Reprogramming muscle proteostasis in cancer cachexia: Transcriptional mechanisms and therapeutic opportunities. Cancer Letters, 664, 218944. https://doi.org/10.1016/j.canlet.2026.218944
Vancouver
Xu B, Jaiswal A, Liu S, Kumar A, Tomaz da Silva M. Reprogramming muscle proteostasis in cancer cachexia: Transcriptional mechanisms and therapeutic opportunities. Cancer Letters. 2027;664:218944. doi:10.1016/j.canlet.2026.218944
BibTeX
@article{Xu2027,
author = {Xu, Bowen and Jaiswal, Aishwarya and Liu, Silin and Kumar, Ashok and Tomaz da Silva, Meiricris},
title = {Reprogramming muscle proteostasis in cancer cachexia: Transcriptional mechanisms and therapeutic opportunities},
journal = {Cancer Letters},
year = {2027},
volume = {664},
pages = {218944},
doi = {10.1016/j.canlet.2026.218944}
}
EUVIMED